Kodu・Aktsiate loetelu・Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Suletud

SektorTervishoid

31.59 3.68

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

29.15

Max

30.85

Põhinäitajad
By Trading Economics
Sissetulek	8.9M -99M
Müük	779K 21M
Aktsiakasum	-1.69
Kasumimarginaal	-477.735
Töötajad	539
EBITDA	23M -98M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+34.25% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	29. okt 2026

Turustatistika
By TradingEconomics
Turukapital	746M 2.2B
Eelmine avamishind	27.91
Eelmine sulgemishind	31.59

Uudiste sentiment

By Acuity

50%

151 / 340 Pingereas Healthcare

Agios Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31. juuli 2026, 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30. juuli 2026, 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29. juuli 2026, 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28. juuli 2026, 20:02 UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27. juuli 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24. juuli 2026, 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22. juuli 2026, 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21. juuli 2026, 19:01 UTC

News

Event

Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Võrdlus sarnastega

Hinnamuutus

Agios Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

34.25% tõus

12 kuu keskmine prognoos

Keskmine 41 USD 34.25%

Kõrge 55 USD

Madal 31 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Agios Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Agios Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

151 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.